Ready-to-use Sterile CAR-T Cell Lines for Leukemia Research

Hits:33   Date: 9/18/2025

Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies. Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).
 
Amsbio Business Development Manager – Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This success inspired new research that demonstrated CAR-T cell therapy targeting multiple B cell proteins offers improved cancer treatment by reducing tumor recurrence from antigen escape, enhancing anti-tumor efficacy through synergistic recognition, overcoming tumor heterogeneity, and potentially improving treatment specificity.”

Ready-to-use sterile cell lines for CAR-T therapy research

 
Dr Petkovic added “Our ready-to-use CAR-T cell line portfolio is extensive and growing. It includes knockout cell lines for TCR, B2M, and CIITA, enabling the modelling of universal CAR-T cells. We can also provide sterile, pathogen- and mycoplasma-free cell lines expressing common CAR targets like BCMA, CD19, CD20, CD22 and more, many of which include the luciferase reporter for simple monitoring. Amsbio now can also offer ready-to-use CAR-expressing cells for assay design/optimization and as positive controls in co-culture assays, as well as bispecific CAR T cells targeting CD19 & CD22.
 
For further information ready-to-use sterile cell lines for CAR-T therapy research please visit https://www.amsbio.com/car-t-cell-research/ or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.
 
Now part of the Europa Biosite group of companies, AMS Biotechnology (Amsbio) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. Amsbio has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows Amsbio to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, Amsbio offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, Amsbio is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.

---------------------

Worldwide HQ

AMS Biotechnology (Amsbio)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com
Web www.amsbio.com
 
North American HQ
 
Amsbio LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com
Web www.amsbio.com